Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update

GlobeNewswire May 1, 2018

Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults

GlobeNewswire April 30, 2018

Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)

GlobeNewswire April 17, 2018

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Benzinga.com  April 13, 2018

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire March 8, 2018

Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire March 7, 2018

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children

GlobeNewswire February 23, 2018

Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update

GlobeNewswire February 20, 2018

Ultragenyx Pharmaceutical, Inc. to Host Earnings Call

Accesswire February 20, 2018

Ultragenyx to Present at Leerink Partners Global Healthcare Conference

GlobeNewswire February 8, 2018

Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President

GlobeNewswire January 29, 2018

Ultragenyx Announces Pricing of Public Offering of Common Stock

GlobeNewswire January 23, 2018

Ultragenyx Announces Proposed Public Offering of Common Stock

GlobeNewswire January 22, 2018

Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE

Business Wire January 8, 2018

Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 

GlobeNewswire January 7, 2018

Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients

GlobeNewswire January 4, 2018

Ultragenyx to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2018

Ultragenyx Sells Priority Review Voucher for $130 million

GlobeNewswire December 18, 2017

Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children

GlobeNewswire December 15, 2017

Market Trends Toward New Normal in The Blackstone Group, Zions, Skyworks Solutions, Continental Building Products, Ultragenyx Pharmaceutical, and Hilltop — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire December 4, 2017